The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain

PLoS ONE

Volumn 3, Issue 3, 2008, Pages

  Fukuda, Tomokazu ^a   Kondo, Yasuyuki ^a   Nakagama, Hitoshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT PROTEIN WITH FORKHEAD ASSOCIATED AND RING FINGER DOMAIN; RING FINGER PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; CELL CYCLE PROTEIN; CHFR PROTEIN, HUMAN; COMPLEMENTARY DNA; MESSENGER RNA; TUMOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; STOMACH CARCINOGENESIS; WESTERN BLOTTING; AMINO ACID SEQUENCE; CELL PROLIFERATION; CHEMISTRY; COLON TUMOR; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTAGENESIS; PATHOLOGY; PHYSIOLOGY; RING FINGER MOTIF; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA, COMPLEMENTARY; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NEOPLASM PROTEINS; RING FINGER DOMAINS; RNA, MESSENGER; UBIQUITIN-PROTEIN LIGASES;

EID: 45849146665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001776     Document Type: Article

References (44)

1. Scolnick DM, Halazonetis TD (2000) Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406: 430-435.
2. Hamilton JP, Sato F, Greenwald BD, Suntharalingam M, Krasna MJ, et al. (2006) Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 4: 701-708.
3. Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, et al. (2006) The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol 41: 133-139.
4. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, et al. (2003) Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63: 8606-8613.
5. Yanokura M, Banno K, Kawaguchi M, Hirao N, Hirasawa A, et al. (2007) Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol Rep 17: 41-48.
6. Yoshida K, Hamai Y, Suzuki T, Sanada Y, Oue N, et al. (2006) DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Anticancer Res 26: 49-54.
7. Summers MK, Bothos J, Halazonetis TD (2005) The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus. Oncogene 24: 2589-2598.
8. Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, et al. (1999) DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18: 7883-7899.
9. Durocher D, Jackson SP (2002) The FHA domain. FEBS Lett 513: 58-66.
10. Williams BR, Mirzoeva OK, Morgan WF, Lin J, Dunnick W, et al. (2002) A murine model of Nijmegen breakage syndrome. Curr Biol 12: 648-653.
11. Jongmans W, Vuillaume M, Chrzanowska K, Smeets D, Sperling K, et al. (1997) Nijmegen breakage syndrome cells fail to induce the p53-mediated DNA damage response following exposure to ionizing radiation. Mol Cell Biol 17: 5016-5022.
12. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, et al. (2001) p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61: 5718-5722.
13. Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, et al. (2002) Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 22: 6521-6532.
14. Takai H, Naka K, Okada Y, Watanabe M, Harada N, et al. (2002) Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. Embo J 21: 5195-5205.
15. Brandes JC, van Engeland M, Wouters KA, Wejenberg MP, Herman JG (2005) CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 26: 1152-1156.
16. Homma N, Tamura G, Honda T, Jin Z, Ohmura K, et al. (2005) Hypermethylation of Chfr and hMLH1 in gastric noninvasive and early invasive neoplasias. Virchows Arch 446: 120-126.
17. Bertholon J, Wang Q, Falette N, Verny C, Auclair J, et al. (2003) Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene 22: 8956-8960.
18. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, et al. (2003) Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 24: 47-51.
19. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, et al. (2003) Epigenetic inactivation of CHFR in human tumons. Proc Natl Acad Sci U S A 100: 7818-7823.
20. Visintin R, Prinz S, Amon A (1997) CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. Science 278: 460-463.
21. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, et al. (2005) Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 37: 401-406.
22. Kang D, Chen J, Wong J, Fang G (2002) The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol 156: 249-259.
23. Strebhardt K, Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321-330.
24. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21-32.
25. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, et al. (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. Embo J 17: 3052-3065.
26. Zhou H, Kuang J, Zhong L, Koo WL, Gray JW, et al. (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20: 189-193.
27. Ogi K, Toyota M, Mita H, Satoh A, Kashima L, et al. (2005) Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol Ther 4: 773-780.
28. Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, et al. (2002) Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res 62: 1797-1801.
29. Bothos J, Summers MK, Venere M, Scolnick DM, Halazonetis TD (2003) The Chfr mitotic checkpoint protein functions with Ubc 1 3-Mms2 to form Lys63-linked polyubiquitin chains. Oncogene 22: 7101-7107.
30. Fukuda T, Mishina Y, Walker MP, DiAugustine RP (2005) Conditional transgenic system for mouse aurora a kinase: degradation by the ubiquitin proteasome pathway controls the level of the transgenic protein. Mol Cell Biol 25: 5270-5281.
31. Wang W, Malcolm BA (1999) Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikCharge Site-Directed Mutagenesis. Biotechniques 26: 680-682.
32. Koinuma. D Shinozaki M, Komuro A, Goto K, Saitoh M, et al. (2003) Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7. Embo J 22: 6458-6470.
33. Daniels MJ, Marson A, Venkitaraman AR (2004) PML bodies control the nuclear dynamics and function of the CHFR mitotic checkpoint protein. Nat Struct Mot Biol 11: 1114-1121.
34. Martinez R, Setien F, Voelter C, Casado S, Quesada MP, et al. (2007) CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma. multiforme. Carcinogenesis.
35. Tokunaga E, Oki E, Nishida K, Koga T, Yoshida R, et al. (2006) Aberrant hypermethylation of the promoter region of the CHFR gene is race in primary breast cancer. Breast Cancer Res Treat 97: 199-203.
36. Littlepage LE, Ruderman JV (2002) Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev 16: 2274-2285.
37. Crane R, Kloepfer A, Ruderman JV (2004) Requirements for the destruction of human Aurora-A. J Cell Sci 117: 5975-5983.
38. Kawai H, Wiederschain D, Yuan ZM (2003) Critical contribution ofthe MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 23: 4939-4947.
39. Kawai H, Lopez-Pajares V, Kim MM, Wiedenschain D, Yuan ZM (2007) RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res 67: 6026-6030.
40. Takai R, Matsuda N, Nakano A, Hasegawa K, Akimoto C, et al. (2002) EL5, a rice N-acetylchitooligosaccharide elicitor-responsive RING-H2 finger protein, is a ubiquitin ligase which functions in vitro in co-operation with an elicitor-responsive ubiquitin-conjugating enzyme, OsUBC5b. Plant J 30: 447-455.
41. Matsuda N, Suzuki T, Tanaka K, Nakano A (2001) Rmal, a novel type of RING finger protein conserved from Arabidopsis to human, is a membrane-bound ubiquitin ligase. J Cell Sci 114: 1949-1957.
42. Matsuda N, Kitami T, Suzuki T, Mizuno Y, Hattori N, et al. (2006) Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem 281: 3204-3209.
43. Privette LM, Gonzalez ME, Ding L, Kleer CG, Petty EM (2007) Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Res 67: 6064-6074.
44. Morioka Y, Hibi K, Sakai M, Koike M, Fujiwara M, et al. (2006) Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer. Anticancer Res 26: 4267-4270.